FCER2 and Parkinson disease: Consequently, inhibiting the AIMP1‐CD23 pathway could effectively alleviate pro‐inflammatory reactions and enhance anti‐inflammatory responses, offering valuable insights for the development of anti‐inflammatory drugs for PD treatment.